{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:36:09Z","timestamp":1769445369964,"version":"3.49.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ampullary carcinoma (AC) is a rare malignancy. It is often classified within biliary tract cancers (BTC) but lacks dedicated treatment guidelines. This post-hoc analysis evaluated outcomes of patients with advanced AC enrolled in the ABC-01, ABC-02, and ABC-03 clinical trials to provide reference data for future studies. All patients with advanced AC formed the \u201cDescriptive cohort,\u201d while those AC treated with cisplatin\u2013gemcitabine (CisGem) comprised the \u201cCisGem-treated cohort.\u201d Among 534 trial participants, 28 (5.24%) had AC, and 17 received CisGem. The median age was 63.93\u2009years, and 75.00% were male. Most patients had metastatic disease at baseline (89.29%). Median follow-up for the CisGem-treated cohort was 10.23\u2009months (95% CI 5.98-14.43). The objective response rate was 23.52%, and disease control was achieved in 58.82% of patients. Estimated median progression-free survival (PFS) and overall survival (OS) were 7.98\u2009months (95% CI, 6.86-8.44) and 11.76\u2009months (95% CI, 5.94-14.88), respectively, comparable to outcomes in other BTCs. No reliable prognostic or predictive factors for PFS, OS, or ORR were identified, likely reflecting the small sample size. This analysis underscores the rarity of advanced AC and the challenges in recruiting adequate numbers for dedicated trials. While CisGem remains an appropriate standard-of-care regimen, modest survival outcomes highlight the need for improved therapies. Molecular profiling has revealed potentially actionable alterations, including HER2 amplification and KRAS mutations, supporting precision oncology approaches. This study provides the most comprehensive reference dataset to date for advanced AC treated with CisGem and emphasizes the importance of international collaboration and molecularly guided research to improve outcomes in this rare malignancy.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf399","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:05:05Z","timestamp":1765544705000},"source":"Crossref","is-referenced-by-count":0,"title":["Advanced ampullary cancer: post-hoc analysis of the ABC-01, ABC-02, and ABC-03 clinical trials"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9696-6122","authenticated-orcid":false,"given":"Angela","family":"Lamarca","sequence":"first","affiliation":[{"name":"Department of Oncology, OncoHealth Institute\u2014Instituto de Investigaciones Sanitarias FJD|Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital , Madrid,","place":["Spain"]},{"name":"Department of Medical Oncology, The Christie NHS Foundation , Manchester,","place":["United Kingdom"]},{"name":"Division of Cancer Sciences, University of Manchester , Manchester,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-1886","authenticated-orcid":false,"given":"Paul","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harpreet S","family":"Wasan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Imperial College Healthcare , London,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A","family":"Hubner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation , Manchester,","place":["United Kingdom"]},{"name":"Division of Cancer Sciences, University of Manchester , Manchester,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mair\u00e9ad G","family":"McNamara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation , Manchester,","place":["United Kingdom"]},{"name":"Division of Cancer Sciences, University of Manchester , Manchester,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1405-7337","authenticated-orcid":false,"given":"Andre","family":"Lopes","sequence":"additional","affiliation":[{"name":"Cancer Research UK & UCL Cancer Centre, University College of London , London,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clatterbridge Cancer Centre , Liverpool,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan W","family":"Valle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation , Manchester,","place":["United Kingdom"]},{"name":"Division of Cancer Sciences, University of Manchester , Manchester,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9186-1604","authenticated-orcid":false,"given":"John","family":"Bridgewater","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, UCL Cancer Institute , London,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"key":"2026012601214461900_oyaf399-B1","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.3390\/curroncol28050293","article-title":"Ampullary carcinoma: an overview of a rare entity and discussion of current and future therapeutic challenges","volume":"28","author":"Rizzo","year":"2021","journal-title":"Curr Oncol"},{"key":"2026012601214461900_oyaf399-B2","doi-asserted-by":"crossref","first-page":"104003","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO clinical practice guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open [Internet]"},{"key":"2026012601214461900_oyaf399-B3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","article-title":"Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study\u2014the UK ABC-01 study","volume":"101","author":"Valle","year":"2009","journal-title":"Br J Cancer"},{"key":"2026012601214461900_oyaf399-B4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2026012601214461900_oyaf399-B5","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026012601214461900_oyaf399-B6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jso.22090","article-title":"Clinical significance of pathologic subtype in curatively resected ampulla of Vater cancer","volume":"105","author":"Kim","year":"2012","journal-title":"J Surg Oncol"},{"key":"2026012601214461900_oyaf399-B7","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/jjco\/hyt237","article-title":"Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy","volume":"44","author":"Shoji","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"2026012601214461900_oyaf399-B8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jhep.2025.01.040","article-title":"A phase III randomized study of first-line NUC-1031\/cisplatin vs. gemcitabine\/cisplatin in advanced biliary tract cancer","volume":"83","author":"Knox","year":"2025","journal-title":"J Hepatol"},{"key":"2026012601214461900_oyaf399-B9","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.annonc.2025.05.338","article-title":"323P early safety and efficacy from the phase IIIb TOURMALINE study of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in advanced biliary tract cancer (aBTC)","volume":"36","author":"Oh","year":"2025","journal-title":"Ann Oncol"},{"key":"2026012601214461900_oyaf399-B10","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/j.annonc.2023.09.1387","article-title":"94MO advanced extrahepatic cholangiocarcinoma: post-hoc analysis of the ABC-01, -02 and -03 clinical trials","volume":"34","author":"Lamarca","year":"2023","journal-title":"Ann Oncol"},{"key":"2026012601214461900_oyaf399-B11","doi-asserted-by":"crossref","first-page":"6996","DOI":"10.3390\/curroncol30070507","article-title":"Ampullary cancer: histological subtypes, markers, and clinical behaviour\u2014state of the art and perspectives","volume":"30","author":"Nappo","year":"2023","journal-title":"Curr Oncol"},{"key":"2026012601214461900_oyaf399-B12","doi-asserted-by":"crossref","first-page":"12676","DOI":"10.1038\/s41598-019-49179-w","article-title":"The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma","volume":"9","author":"Zimmermann","year":"2019","journal-title":"Sci Rep"},{"key":"2026012601214461900_oyaf399-B13","doi-asserted-by":"crossref","first-page":"101994","DOI":"10.1016\/j.suronc.2023.101994","article-title":"Elevated CA 19-9 is associated with worse survival in patients with resected ampullary adenocarcinoma","volume":"51","author":"Boyev","year":"2023","journal-title":"Surg Oncol"},{"key":"2026012601214461900_oyaf399-B14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7150\/jca.16200","article-title":"The prognostic impact of the carcinoembryonic antigen in ampullary cancer\u2014a retrospective single center study","volume":"8","author":"Fuellgraf","year":"2017","journal-title":"J Cancer"},{"key":"2026012601214461900_oyaf399-B15","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.3390\/cancers15245772","article-title":"Ampullary adenocarcinoma: a review of the mutational landscape and implications for treatment","volume":"15","author":"Tsagkalidis","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026012601214461900_oyaf399-B16","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"2026012601214461900_oyaf399-B17","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf399\/65879712\/oyaf399.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf399\/65879712\/oyaf399.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf399\/65879712\/oyaf399.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T06:21:50Z","timestamp":1769408510000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf399\/8379842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf399","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,14]]},"article-number":"oyaf399"}}